Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
- Revenue in EUR (TTM)45.41m
- Net income in EUR-38.76m
- Incorporated1999
- Employees188.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurofins Cerep SA | 40.46m | 7.15m | 93.82m | 207.00 | 13.11 | 1.31 | 9.81 | 2.32 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Ose Immunotherapeutics SA | 2.22m | -34.84m | 103.24m | 68.00 | -- | 2.04 | -- | 46.53 | -1.59 | -1.59 | 0.1009 | 2.26 | 0.0181 | -- | 0.4821 | 34,671.88 | -28.42 | -7.66 | -33.45 | -9.27 | -- | -- | -1,569.85 | -26.10 | -- | -- | 0.4331 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Abionyx Pharma SA | 4.33m | -4.60m | 131.22m | 51.00 | -- | 23.35 | -- | 30.33 | -0.1317 | -0.1317 | 0.1238 | 0.1582 | 0.3033 | 17.39 | 7.16 | 84,823.53 | -32.25 | -26.53 | -43.11 | -38.31 | 17.78 | 15.59 | -106.31 | -131.06 | 1.35 | -- | 0.4281 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Adocia SA | 10.35m | -9.71m | 133.33m | 77.00 | -- | -- | -- | 12.88 | -0.5622 | -0.5622 | 0.6343 | -0.0338 | 0.4068 | -- | 2.55 | 134,428.60 | -38.16 | -47.62 | -184.08 | -104.50 | -- | -- | -93.83 | -331.17 | 1.12 | -14.58 | 1.06 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| Innate Pharma SA | 6.00m | -46.05m | 133.68m | 181.00 | -- | 25.55 | -- | 22.28 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Maat Pharma SA | 3.92m | -31.13m | 137.04m | 60.00 | -- | 14.16 | -- | 34.94 | -2.15 | -2.15 | 0.270 | 0.5141 | 0.0786 | 11.22 | 0.5785 | 65,366.67 | -62.39 | -41.51 | -90.20 | -51.87 | 61.68 | -- | -793.83 | -976.99 | 2.21 | -29.53 | 0.6346 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Sensorion SA | 0.00 | -28.09m | 174.05m | 68.00 | -- | 1.78 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Transgene SA | 7.24m | -36.78m | 230.87m | 147.00 | -- | -- | -- | 31.89 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Cellectis SA | 69.41m | -29.72m | 243.32m | 224.00 | -- | 2.89 | -- | 3.51 | -0.2963 | -0.2963 | 0.69 | 1.17 | 0.2234 | -- | 8.58 | 309,846.30 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Eurobio Scientific SA | 162.09m | 2.36m | 244.44m | 380.00 | 101.66 | 1.32 | 13.72 | 1.51 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Genfit SA | 45.41m | -38.76m | 326.24m | 188.00 | -- | 6.21 | -- | 7.18 | -0.7737 | -0.7737 | 0.9083 | 1.05 | 0.2207 | 519.75 | 0.9236 | 252,277.80 | -18.84 | -7.73 | -23.25 | -9.79 | 95.42 | 95.68 | -85.35 | -37.15 | 3.74 | -10.87 | 0.1223 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Valneva SE | 179.91m | -102.16m | 717.79m | 700.00 | -- | 4.76 | -- | 3.99 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
Data as of Feb 11 2026. Currency figures normalised to Genfit SA's reporting currency: Euro EUR
6.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 683 Capital Management LLCas of 07 Jan 2026 | 2.94m | 5.88% |
| CPR Asset Management SAas of 30 Sep 2025 | 148.57k | 0.30% |
| State Board of Administration of Florida Retirement Systemas of 30 Sep 2025 | 68.97k | 0.14% |
| Sunny Asset Management SAas of 30 Dec 2025 | 60.00k | 0.12% |
| OFI Invest Asset Management SAas of 29 Jan 2026 | 31.13k | 0.06% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 12.72k | 0.03% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 7.45k | 0.02% |
| RAM Active Investments SAas of 30 Jun 2025 | 5.31k | 0.01% |
| Mandarine Gestion SAas of 30 Jun 2025 | 3.00k | 0.01% |
| Friedland Gestion SASas of 25 Jul 2025 | 1.80k | 0.00% |
More ▼
Data from 30 Jun 2025 - 01 Feb 2026Source: FactSet Research Systems Inc.
